Last reviewed · How we verify
fibroblast growth factor
Fibroblast growth factor (FGF) promotes cell proliferation, differentiation, and angiogenesis by binding to FGF receptors on target cells.
Fibroblast growth factor (FGF) promotes cell proliferation, differentiation, and angiogenesis by binding to FGF receptors on target cells. Used for Wound healing and tissue repair, Diabetic ulcers.
At a glance
| Generic name | fibroblast growth factor |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Drug class | Growth factor |
| Target | Fibroblast growth factor receptor (FGFR) |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Wound Care |
| Phase | FDA-approved |
Mechanism of action
FGF is a naturally occurring signaling protein that activates fibroblast growth factor receptors (FGFRs) on the cell surface, triggering intracellular cascades that stimulate tissue repair, wound healing, and neovascularization. This mechanism is leveraged therapeutically to promote healing in damaged or ischemic tissues, particularly in wound care and tissue regeneration applications.
Approved indications
- Wound healing and tissue repair
- Diabetic ulcers
Common side effects
- Local injection site reactions
- Erythema
- Edema
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) (PHASE2)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (PHASE2)
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fibroblast growth factor CI brief — competitive landscape report
- fibroblast growth factor updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI